Rapamycin (sirolimus)

DRUG3 trials

Sponsors

University of Chicago, Umoja Biopharma

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)Grade 3b Follicular LymphomaHigh Grade B Cell LymphomaLymphoma Non-HodgkinLymphoma, B CellMultiple Myeloma (MM)Multiple Myeloma in RelapseNeoplasm Metastasis

Phase 1

Rapamycin With Grapefruit Juice for Advanced Malignancies

CompletedNCT00375245

University of ChicagoTumors, Neoplasm Metastasis

Start: 2006-09-30End: 2012-05-31Updated: 2014-01-17

A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

Not yet recruitingNCT07735533

Umoja BiopharmaLymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma +4

Start: 2026-08-01End: 2031-08-01Target: 274Updated: 2026-08-17

A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

Not yet recruitingNCT07735546

Umoja BiopharmaMultiple Myeloma in Relapse, Multiple Myeloma (MM)

Start: 2026-10-01End: 2029-12-31Target: 100Updated: 2026-08-17